Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon s 2000 Revenues Triple While Losses Widen Sharply

NEW YORK, March 7 - Lexicon Genetics' year-end revenues increased 205 percent to $14.5 million from over $4.7 million in 1999, while increased expenses and stock compensation drove its losses up substantially for 2000, the company reported Wednesday.

The company attributed its revenue increase to a new alliance with Bristol-Myers Squibb in which Lexicon provides gene function information for drug targets in return for $15 to $25 million in access and delivery fees; as well as its other nine functional genomics collaborations with pharma and biotech; and license fees from its sub-licensees.

The jump in expenses, to $49.9 million in 2000 from $12.8 million in 1999, derives partially from a one-time stock-based compensation expense of $20.9 million. The company's sales, general, and administrative expenses also increased 168 percent to $8.3 million from $2.9 million in 1999, and its R&D expenses rose 42 percent to $20.8 million, from $14.6 million in 1999.

As part of its sales, general, and administrative expenses, Lexicon spent $800,000 pursuing patent infringement litigation against rival knockout mouse company Deltagen, a suit Lexicon initiated in late May.

The company posted net losses of $26.1 million or 63 cents per common share, compared to $13.0 million, or 53 cents per share for 1999.  These losses, which included the stock-based compensation, greatly exceeded Wall Street's expectation of 32 cents per share, based on a survey of two brokers conducted by FirstCall/Thomson Financial.

As of December 31, 2000, Lexicon had cash assets of $202 million in the bank. In April of 2000, the company filled its coffers with $220 million netted in an IPO.

"Lexicon performed exceptionally well in the year 2000 and met or exceeded all of our milestones," Arthur Sands, Lexicon CEO, said in a statement. "Our strong cash position and the power of our technology, combined with our highly experienced drug discovery team, places Lexicon on a trajectory to become a leading biopharmaceutical company of the post-genome era."

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.